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For drug-compliant patients, poor responses to tuberculosis (TB) treatment might be attributable to subtherapeutic drug con-
centrations. An impaired absorption of rifampin was previously reported for patients with diabetes mellitus (DM) or HIV. The
objectives of this study were to determine whether TB drug pharmacokinetics differed in Peruvian TB patients with DM or HIV.
In this cross-sectional study, TB patients, recruited from health centers in Lima, Peru, had blood samples taken at 2 and 6 h after
directly observed TB drug ingestion, to determine plasma concentrations of rifampin. Of 105 patients, 50 had TB without a co-
morbidity, 26 had coexistent DM, and 29 had coexistent HIV. Unexpectedly, the overall median 2- and 6-h levels of rifampin
were 1.6 and 3.2 mg/liter, respectively, and the time to the peak concentration was 6 h (slow absorber) instead of 2 h (fast ab-
sorber) for 61 patients (62.2%). The geometric mean peak concentration of drug in serum (Cmax) was significantly higher in fast
absorbers than in slow absorbers (5.0 versus 3.8 mg/liter; P 0.05). The rifampin Cmax was significantly lower in male patients
than in female patients (3.3 versus 6.3 mg/liter; P< 0.001). Neither slow nor fast absorbers with comorbidities (DM or HIV) had
significantly different Cmax results compared to those of TB patients without comorbidities. An analysis of variance regression
analysis showed that female gender (P< 0.001) and the time to maximum concentration of drug in serum (Tmax) at 2 h (P
0.012) were independently correlated with increased exposure to rifampin. Most of this Peruvian study population exhibited
rifampin pharmacokinetics different from those conventionally reported, with delayed absorption and low plasma concentra-
tions, independent of the presence of an HIV or DM comorbidity.
Over the last few decades, noncommunicable diseases (NCDs)have exhibited an increasing trend in developing countries
(4), and the disease burden falls predominantly in these regions in
terms of health and economic impacts (14). Diabetes mellitus
(DM) is one of the major NCDs, and global statistics estimate an
increase from 194 million people with this disease in 2003 to 330
million in 2030 (42). A substantial proportion (75%)will be living
in developing countries (32), where concurrently, many commu-
nicable diseases, such as tuberculosis (TB), remain highly preva-
lent, particularly in countries with high rates of HIV infection
(40).
The increased risk of active TB in diabetic patients is now well
recognized (2, 31), and the danger of the convergence of these two
global pandemics is clear, with 8 of the 10 countries with the high-
est incidences of DM in the world also presenting a major burden
of TB (41).
Although less prevalent than DM, HIV is a more potent risk
factor for TB and is a major cause of morbidity and mortality in
HIV patients in low-income countries (9).
Most TB patients treated with standardized-dosing drug regi-
mens exhibit a high cure rate with few side effects (19). Poor com-
pliance with treatment is the major cause of treatment failure and
relapse. Nevertheless, recently reported in vitro and animal model
data suggest that the pharmacokinetic variability of antitubercu-
losis drugs might be another factor to be considered (35). There-
fore, an unknown percentage of cases with a poor response to
treatment (defined by clinical failure or relapse) may be attribut-
able to low drug concentrations (6, 15, 22, 27, 36). Therapeutic
drug monitoring (TDM) has been proposed as a potential ap-
proach for patients failing therapy despite appropriately executed
directly observed therapy (DOT) (27). Although TB drug dosing
is based upon patient weight banding, antituberculosis drug phar-
macokinetics (PK) may be altered by several factors, including
age, gender, ethnicity, drug formulations, drug interactions, and
gastroenteritis (6). Impaired absorption was previously suggested
to occur in some patients with DM, HIV/AIDS, or cystic fibrosis
(7, 12, 23, 33).
Culture conversionmay be delayed in treated TB patients with
DM; the only (small) study to evaluate PK in diabetic TB patients
suggested that serum drug concentrations may be lower than
those in TB patients without DM (23). For patients with HIV,
conflicting results have been reported (7, 8, 11, 25, 29, 33, 37),
although it was proposed that impaired pharmacokinetics leading
to low drug concentrations could contribute to acquired drug
resistance in fully adherent patients (39). This operational re-
search study was undertaken to determine whether TB drug PK
differed in PeruvianTBpatients with a comorbidity ofDMorHIV
after controlling for potential confounders such as body weight
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(and, thus, the dose received in mg/kg of body weight) and intes-
tinal parasitic infection.
MATERIALS AND METHODS
Study design, participants, and setting. This cross-sectional observa-
tional study was conducted in Lima, Peru, from July to December 2009.
TB patients who had received at least 15 days of treatment were recruited
from health centers in Lima where directly observed therapy (6 days per
week during the intensive phase and twice a week during themaintenance
phase) is provided through the DOTS program of the Peruvian National
Tuberculosis Program (NTP). Patients unwilling or unable to give in-
formed consent were excluded. Patients with known HIV disease or DM
were particularly sought, with the aim of recruiting at least 25 individuals
for each subgroup.
Field methods. At the interview, a semistructured questionnaire was
administered to all participants. Particular emphasis was put on detecting
previous gastrointestinal surgery, ongoing chronic diarrhea (three or
more unformed stools per day for15 days), and other factors that could
contribute to malabsorption. Gender, age, height (cm), and weight (kg)
were recorded, and the body mass index (BMI) was calculated.
Blood was drawn at the health center by dedicated study staff into
10-ml lithium heparin tubes at two time points, 2 and 6 h, after directly
observed TB drug ingestion, and a fecal sample was collected for parasi-
tological analysis.
Laboratory methods. Blood samples were refrigerated, kept in the
dark, and transported to the Universidad Peruana Cayetano Heredia
(UPCH), where serum was separated (by centrifugation at 2,000 rpm for
10min) between 2 and 5 h after sample collection. Aliquots were stored at
70°C until they were batched and transported to the pharmacokinetics
laboratory of the Liverpool School of Tropical Medicine (LSTM), where
rifampin (RIF) levels were measured by using a validated high-perfor-
mance liquid chromatography (HPLC) technique. All sample prepara-
tions were carried out in a darkened room. Two hundred microliters of
each sample was assayed alongside a plasma calibration curve (0 to 32
g/ml) and quality control samples with a low concentration of 1.5 g/
ml, a medium concentration of 17 g/ml, and a high concentration of 26
g/ml. Plasma was precipitated by using 50 l of an ethanol-containing
internal standard (butyl 4-hydroxybenzoate at 16g/ml), followed by the
addition of 1ml ofmethanol, and vortexed for 20 s. Tubes were incubated
at 4°C for 1 h and then centrifuged at 2,000 g for 10 min. One milliliter
of the upper solvent layer was transferred into a clean glass soda tube,
evaporated to dryness under a stream of nitrogen at 30°C, and reconsti-
tuted in 120 l methanol, and 100 l of sample was then injected onto a
Shimadzu LC 2010 HT HPLC system, with detection at 254 nm. Data
acquisition was performed by using Chromeleon (Dionex). The com-
pounds were separated on a Luna C8 150- by 4.6-mm 5-m column
(Phenomenex Inc.) protected by a LiChrosphere Si 60 5-m column
(VWR) using a gradient system, with themobile phase containing solvent
A (35% acetonitrile and 65% 50 mM ammonium formate [pH 5], ad-
justed with formic acid) and solvent B (70% acetonitrile and 30% 50mM
ammonium formate [pH 5], adjusted with formic acid). The column
temperature was set at 30°C.
The assay was linear (r2 0.99) in the concentration range of 0 to 32
g/ml, with intra- and interday precisions with a 13% coefficient of
variation (CV) and a11% CV, respectively. The lower limit of quanti-
fication (LLOQ) (0.5g/ml) has been accepted as the lowest point on the
standard curve, with a relative standard deviation of less than 10% and a
5:1 signal-to-noise ratio. The determination of RIF stability following
three freeze-thaw cycles showed that for all quality control (QC) samples,
there was a9% CV in RIF concentrations. RIF stability after heat inac-
tivation showed a11% CV in RIF concentrations.
Serum glucose levels were measured for all patients, and glycosylated
hemoglobin levels (HbA1c) were measured in diabetic patients. Fecal
samples were concentrated by the Formol ethermethod and examined for
the presence of ova, cysts, and parasites within 24 h of collection.
Measurements of pharmacokinetic outcomes. Two- and six-hour
plasma concentrations were determined, and for each patient, the maxi-
mum serum drug concentration (Cmax) was estimated as the higher of the
two measured concentrations; the Tmax for each patient was the time
point at which the Cmax occurred.
Cmax values were also categorized as normal (8mg/liter), low (4 to 8
mg/liter), or very low (4 mg/liter), in accordance with data reported
previously (28, 38).
Statistical analysis. Data were double entered into an EpiData data-
base; checked with EpiData software, version 3.1; and analyzed with
STATA, version 10.
Demographic and general characteristics of the three patient groups
(TB, TB-HIV, and TB-DM) were compared by using the chi-square (2)
test for the comparison of proportions and the Student t test for contin-
uous and normally distributed variables. Non-normally distributed data
were analyzed by using theMann-Whitney test. The primary comparison
of interest was between-group serum rifampin levels at 2 and 6 h postdos-
ing and were analyzed with the independent-sample t test on the natural-
logarithm-transformed pharmacokinetic data. Patients with TB and no
other comorbidity (“TB”) were compared with (i) patients with TB and
DM (“TB-DM”) and (ii) patients with TB and HIV (“TB-HIV”). A strat-
ified analysis was performed to assess the effects of gender, age, BMI, and
the dose of rifampin administered. The dose of rifampinwas calculated by
dividing the totalmilligrams of rifampin received by theweight of patients
in kg.
A multivariate analysis of variance was performed to assess the varia-
tion in rifampin pharmacokinetics (Cmax) attributable to the presence of a
comorbidity (HIV or DM), gender, BMI, and other variables that
emerged from the univariate analyses.
Ethics and institutional review.The study protocol and consent form
were approved by the ethics committee of the London School of Hygiene
and Tropical Medicine (LSHTM), the institutional review boards of the
UPCH and Dirección de Salud-II (DISA-II) Lima Sur (regional Ministry
of Health), and the ethics committee of the Hospital Nacional Dos de
Mayo, Lima, Peru.
RESULTS
Participant characteristics. Participant characteristics are shown
in Table 1. Of 113 patients recruited into the study, PK data were
available for 105 (mean age, 36.9 years; 63.8%male patients); for 5
of these patients, only one measurement was available, because
either the sample was insufficient or the 6-h sampling time was
missed. Sixty-one patients were in the intensive phase and 44 were
in the continuation phase of their treatment; 70.5% of cases were
new cases. The majority of patients (87%) had pulmonary TB; 77
had microbiologically confirmed TB, while 28 were receiving
treatment based on clinicoepidemiological and radiological
grounds. Fifty patients had TB without a comorbidity (TB, the
baseline group for comparison), 26 had coexistent DM (TB-DM),
and 29 had coexistent HIV (HIV-TB). Diabetic TB patients were
significantly older and had significantly higher BMIs and signifi-
cantly higher blood glucose levels than TB patients without a co-
morbidity (P 0.001 for all). ThemedianHbA1c level for diabetic
patients was 8.3% (range, 4.6 to 12.8%; data were available for
only 23/26 patients).
A significantly higher proportion of HIV-TB patients were
male, but otherwise, this group did not differ significantly from
TB patients without a comorbidity. The mean CD4 count, avail-
able for only 14 patients, was 298 cells/l. Eight HIV patients were
receiving antiretroviral therapy, none with protease inhibitors.
The dose of rifampin (provided by IQ-farma and Infarmasa-
Corporación, both from Peru) recommended by the Peruvian
NTP is 10 mg/kg/day to a maximum of 600 mg per day for both
Requena-Méndez et al.
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the intensive and maintenance phases. The calculated dosage re-
ceived was significantly lower in the DM-TB group (Table 1) and
was significantly lower overall in males (9.5 mg/kg; range, 8.3 to
10.5mg/kg) than in females (10.5mg/kg; range, 9.3 to 11.0mg/kg)
(P 0.004 by a Welch t test).
Pharmacokinetic analysis. (i) Rate of rifampin absorption
(Tmax). Unexpectedly, the Tmax was at 6 h instead of at 2 h for 61
patients (62.2%). For further analysis, subjects were therefore di-
vided into 2 groups, (i) fast absorbers, with Tmax at 2 h, and (ii)
slow absorbers, with Tmax at 6 h. Being a slow absorber (with a
delayed Tmax) was not associated with gender, age group, DM or
HIV comorbidity, phase of treatment, intestinal parasitic infec-
tion, or dose received (data not shown).
(ii) Peak rifampin level (Cmax).Data are expressed as geomet-
ric means since the analysis was performed with the natural loga-
rithm of the Cmax. Overall, median 2- and 6-h levels of rifampin
were 1.6 mg/liter (range, 0 to 18 mg/liter) and 3.2 mg/liter (range,
0 to 16 mg/liter), respectively. The magnitude of the geometric
mean peak rifampin absorption (Cmax) was 4.2 mg/liter (range,
0.5 to 18mg/liter). The geometricmeanCmax of fast absorbers was
significantly higher (5.0 mg/liter) than that of slow absorbers (3.8
mg/liter) (P 0.05).
The rifampin Cmax was significantly lower in male than in fe-
male patients (3.3 versus 6.3 mg/liter; P  0.001), and this effect
was consistent in both fast (4.4 versus 6.7mg/liter; P 0.009) and
slow (2.7 versus 6.1 mg/liter; P 0.001) absorbers (Fig. 1).
Neither slow nor fast absorbers with comorbidities had results
that were significantly different Cmax from those of TB patients
TABLE 1 Participant characteristics by subgroupa
Parameter
Value for group
TB (n 50) DM-TB (n 26) HIV-TB (n 29) All (n 105)
% male patients 48.0 65.4 90.0*** 63.8
Mean age (yr) (range) 31.1 (18–65) 51.3 (29–79)*** 34.1 (24–48) 36.9 (18–79)
No. of patients with microbiologically confirmed TB (%) 38 (76.0) 22 (84.6) 17 (58.6) 77 (73.3)
Mean BMI (kg/m2) (range) 23.3 (18.4–29.6) 27.5*** (21.9–36.3) 22.8 (15.8–34.8) 24.2 (15.8–36.3)
No. of patients with diarrhea15 days (%) 1 (2.0) 3 (11.5) 2 (6.9) 6 (5.7)
No. of patients with chronic diarrhea (%) 0 (0) 0 (0) 2 (6.9) 2 (1.9)
No. of patients with intestinal surgery (%) 4 (8.0) 4 (15.4) 2 (6.9) 10 (9.5)
Mean blood glucose level (mg/dl) (range)b 92.7 (40–159) 178.8 (85–441)*** 92.7 (61–123) 114.2 (40–441)
No. of patients with pathogenic parasites (%)c,d 4 (8.0) 1 (3.9) 4 (14.8) 9 (8.7)
No. of patients with nonpathogenic parasites (%)c 16 (32.0) 12 (46.2) 7 (25.9) 35 (34.0)
No. of patients with intensive-phase treatment (%) 31 (62.0) 13 (50.0) 17 (58.6) 61 (58.1)
Median dose of rifampin received (mg/kg) (range) 10.1 (7.4–12.6) 8.8 (5.7–10.9)*** 10.3 (6.7–15.8) 9.8 (5.7–15.8)
a Proportions are expressed as cases/total number of patients (percent). Numerical values are expressed as means (ranges). All the tests compared the DM-TB or HIV-TB group to
the TB (non-HIV, non-DM) group. Continuous variables were analyzed by using an independent t test, and categorical variables were analyzed with a Pearson 2 test. BMI, body
mass index. ***, P 0.001, compared with the TB group without a comorbidity.
b Results were not available for one TB patient (no comorbidity), one TB-DM patient, and two TB-HIV patients.
c Results were not available for 2 HIV patients.
d Two HIV patients had asymptomatic giardiasis, 1 patient had Cyclospora cayetanensis, 1 patient had Cryptosporidium parvum, and 1 diabetic patient also had giardiasis; in the TB
group, all 4 patients had giardiasis.
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FIG 1 The rifampin Cmax is lower in males regardless of the Tmax.
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without comorbidities (Table 2). The rifampin dosage received
had no discernible effect upon Cmax values among either slow or
fast absorbers.
Thirty-six patients (34.3%) had undetectable rifampin levels at
2 h, two of whom also had undetectable levels at 6 h (Fig. 2). In the
fast-absorber group, 10 patients (27.0%) had Cmax values of 4
mg/liter, 23 (62.2%) had rifampin levels between 4 and 8mg/liter,
and only 4 (10.8%) had values that are regarded as acceptable
normal levels. For slow absorbers, 31 (50.8%) had Cmax values of
4 mg/liter, 20 (32.8%) had levels between 4 and 8 mg/liter, and
10 patients (16.3%) had normal levels (8 mg/liter) (Fig. 2).
A multivariate analysis was performed, where the dependent
TABLE 2 Determinants of Cmax in fast and slow absorbers of rifampin
a
Determinant
Geometric mean Cmax
(mg/liter) for fast
absorbers (2 h)
(n 37)
P value for fast
absorbers
Geometric mean Cmax
(mg/liter) for slow
absorbers (6 h)
(n 61)
P value for slow
absorbers
TB comorbidity
DM-TB 5.1 0.99 3.4 0.29
HIV-TB 4.8 0.76 3.1 0.10
None 5.1 4.5
Sex
Male 4.4 0.009 2.7 0.001
Female 6.7 6.1
Phase of treatment
Intensive phase 5.5 0.64 3.4 0.06
Maintenance phase 4.9 4.7
Age group
18–30 yr 5.0 0.93 4.4 0.61
31–40 yr 4.9 3.5
40 yrs 5.2 3.5
Presence of intestinal parasites
Yes 3.9 0.40 3.0 0.49
No 5.1 3.8
Overall geometric mean 5.0 3.8
a Numerical values are expressed as geometric means. Comparisons of groups were made between DM-TB or HIV-TB group and the TB (non-HIV, non-DM) group. All the
variables were analyzed by using the independent-sample t test on the natural logarithm-transformed data.
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FIG 2 Frequency distribution of Cmax categories by slow- and fast-absorber subgroups.
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variable was “the natural logarithm of Cmax.” We built a model to
assess the independent effect of the time of absorption, gender,
comorbidity (DM or HIV associated with TB), and rifampin dose
received. The rifampin dose received was not found to have an
effect upon theCmax. However, males were found to receive lower
doses than females. Therefore, it was decided to include the vari-
able rifampin dose received in the multivariate analysis. Other
variables, such as age, serum glucose level, or the presence of in-
testinal parasites, were not significantly associated and were ex-
cluded during the building of the model (Table 3). The rifampin
dose received did not significantly influence the Cmax in our
model. However, males were found to have Cmax levels 1.9 times
lower than those of females (confidence interval [CI], 1.42 to 2.56;
P value, 0.001), and fast absorbers also differed significantly
compared to slow absorbers (0.71; CI, 0.54 to 0.93; P value, 0.012)
in our model.
Since (unexpectedly) many patients had undetectable levels at
2 h and many others had rifampin levels that were higher at 6 h
than at 2 h, the area under the curve could not be calculated.
It is recommended that rifampin be taken on an empty stom-
ach, as a modest reduction in absorption was previously observed
when rifampin was taken with food. Information on oral intake
was available for only 48 patients, 12 of whom fasted for at least 2
h before taking the treatment. In this small, underpowered sub-
group analysis, oral intake was not associated with a delayed Tmax
or with a reduced Cmax. Two Peruvian companies provide rifam-
pin to the NTP. Health centers do not necessarily receive only a
single brand, and it was possible to reliably identify the manufac-
turer for only 48 patients. Thirty-eight patients (80.9%) had been
treated with drugs from manufacturer “A,” while 9 (19.2%) had
been treated with drugs produced by manufacturer “B.” The me-
dian plasma rifampin Cmax values achieved did not differ between
manufacturers (4.5 mg/liter for manufacturer A [range, 0 to 15.6
mg/liter] versus 4.9 mg/liter [range, 1.5 to 12.9 mg/liter] for man-
ufacturer B; P 0.7).
The treatment responses of 99 out of the 105 TB patients were
evaluated 6 months after the completion of treatment. Ten pa-
tients were found to have multidrug-resistant TB (MDR-TB) and
changed treatment schema after the PK analysis and were there-
fore not included in this subanalysis. A further 29 patients either
had abandoned treatment and restarted several months later or
were lost to follow-up. Of the remaining evaluable 60 patients, 55
were considered completely cured and relapse free 6 months after
finishing treatment, and 5 had an unfavorable outcome. Out of
these 5 patients, 2 of them were diabetic patients, 2 were HIV
positive (1 of the HIV-positive patients had extrapulmonary cere-
bral TB without improvement despite prolonged therapy), and 1
patient had no comorbidity. Four of these 5 patients had an ab-
sorption delay (Tmax at 6 h instead of at 2 h), 3 of them had very
low Cmax levels, and the other 2 had low levels (4 to 8 mg/liter).
Among the 55 patients with a good outcome, 31 patients (56%)
had delayed absorption, 18 patients (33%) had Cmax levels of4
mg/liter, 26 (47%) had low levels, and 8 (15%) had normal Cmax
levels. For 3 of these patients with a good outcome, neither the
Tmax nor theCmax could be calculated because only 1 blood sample
was available.
DISCUSSION
The key finding of this research study, carried out under real-life
field conditions and not in the controlled environment of a dedi-
cated PK unit, is that measured serum rifampin levels in patients
receiving directly observed TB treatment in the Peruvian NTP
were highly variable and very frequently well below what is con-
ventionally regarded as a therapeutic range. This study was de-
signed to determine to what extent a DM or HIV comorbidity
might impair rifampin pharmacokinetics, but neither of these
conditions had any demonstrable effect on either the rate of ri-
fampin absorption (Tmax) or themagnitude of absorption (Cmax).
Instead, therewas awidespread perturbation ofwhat is considered
to be “normal” rifampin pharmacokinetics across all patient
groups. Specifically, two-thirds of patients had delayed rifampin
absorption, with higher levels at 6 h than at 2 h postdosing, and for
only one-quarter of patients was a measured rifampin serum level
(whether at 2 or 6 h) above the 8-mg/liter threshold regarded as
necessary for therapeutic efficacy.
Although therapeutic drug monitoring (TDM) is neither
widely used nor recommended during TB treatment, it is widely
held that abnormal TB drug pharmacokinetics may adversely in-
fluence outcomes, with potential consequences including treat-
ment failure, relapse or death, prolonged infectiousness, and the
development of acquired drug resistance (5, 39). In addition,
TDMmight contribute not only to the identification patients with
low levels of rifampin but also to a shrinking of the duration of
treatment (13), since there are many patients in directly observed
therapy (DOT) programs who complete the treatment in 1 year
rather than in 6 months.
We observed very low levels of rifampin at 2 h in 68.6% of
patients, which is in accordance with data from other studies (3,
38). Moreover, 36 patients (34.3%) had undetectable levels at 2 h,
when the peak concentration after oral administration theoreti-
cally occurs (23, 26). Wilkins et al. previously reported consider-
able interindividual variability in rifampin pharmacokinetics in
SouthAfrica and suggested that highly variable rates of absorption
could significantly impact theCmax, since, as further confirmed by
our data here, slower absorption leads to lower peak plasma con-
centrations (43). In our study, 61 patients had higher levels of
rifampin at 6 h than at 2 h, which we attributed to a delay in
absorption; thus, the Tmax varied significantly. Aside from inter-
individual variability, we wanted to explore other potential expla-
nations for our startling findings. A strength of this study was its
real-life execution in health centers; thus, samples were taken
TABLE 3Multivariate regression model of the independent association
of various variables with exposure to rifampina
Variable
Proportional
difference CI
P
valued
Tmax (6 h) 0.71
b 0.55–0.93 0.012
Sex (female) 1.91c 1.42–2.56 <0.001
Rifampin dose received 1.05 0.96–1.14 0.299
Comorbidity
HIV 0.98 0.71–1–37 0.926
DM 0.99 0.71–1.37 0.931
a The model was considered based on the natural logarithm of the Cmax values. The
proportional difference was calculated as the exponential of the coefficient obtained for
each variable in the multivariate model.
b For interpretations of the proportional difference, Cmax levels in slow absorbers were
29% lower than Cmax levels in fast absorbers.
c For interpretations of the proportional difference, Cmax levels in women were 91%
higher than those in men.
d Boldface indicates significant difference.
Rifampin Blood Levels in TB Patients with Comorbidity
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from patients doing what they do every day and not under the
tightly controlled conditions of a dedicated PK ward. As such,
despite the known effect of food upon the pharmacokinetics of
rifampin (and other TB drugs) (5, 34, 44), many patients did not
fast before taking treatment; indeed, fasting is not a feature of the
Peruvian NTP guidelines. In the small subgroup of patients for
whom oral intake data were available (48 of 105), we could not
demonstrate any effect of food on the Cmax or Tmax.
Men received a lower mg/kg dosage and had lower maximum
rifampin levels thanwomen.However, even after adjusting for the
rifampin dosage received in the multivariate analysis, men had
significantly lower plasma levels than women, a finding reported
previously (21, 38) and likely due to an increased volume of dis-
tribution (24).
No association was found between rifampin PK and intestinal
parasitosis, which affected almost 10%of participants, which does
not support the hypothesis that intestinal parasitosis might affect
TB treatment outcomes through a PK-related mechanism (18).
The absorption of orally administered drugs can be modified
by the nonspecific adsorption of drugs to excipients in formula-
tions (5); a study in South Africa documented a poor relative
bioavailability of rifampin from some fixed-dose combinations
(30). It was not clear whether bioequivalence studies had been
performed for the two generic preparations of rifampin in use
(10); although data were incomplete, we were unable to demon-
strate a difference in the PK results for each preparation.
If DM is confirmed to be an independent risk factor for treat-
ment failure (1), our data suggest that this is not related to de-
ranged pharmacokinetics of rifampin, nor is it associated with
hyperglycemia, although the limited pharmacokinetic analysis
might hamper the assessment of the effect of DM on the pharma-
cokinetics of rifampin. It remains controversial whether a signif-
icant malabsorption of antimycobacterial drugs occurs in HIV
patients (9, 11, 29, 33, 37) and, if so, whether this is associatedwith
treatment failure or the emergence of drug resistance. Although a
crude analysis revealed marginally reduced Cmax values in HIV
patients (data not shown), after stratifying data by the Tmax, no
associations remained between the rifampin level and HIV status
in either fast or slow absorbers. HIV-related achlorhydria, HIV
enteropathy (17), and opportunistic infections of the intestinal
tract were reported previously (5, 16) to be risk factors for a poor
treatment outcome; we did not explore these risk factors other
than in the search for intestinal parasites.
The main limitation of this work was the inability to calculate
the 0- to 6-h area under the PK curve (AUC). We sampled only
two time points, 2 and 6 h, for pragmatic and logistic reasons and
because this approach was previously successful. However, the
real Cmax might have occurred between the 2- and 6-h samplings,
and furthermore, the unexpected finding of so many measure-
ments below the limit of detection and the fact that a considerable
proportion of patients had their Tmax at 6 h rendered AUC calcu-
lations futile. While we regarded the conduct of the study under
real-life circumstances as being important and a strength of the
data, we were unable to adequately control and reliably measure
concomitant oral intake for all participants. Gastrointestinal upset
is common in TB patients, and many gain relief by taking medi-
cines with food or juice; a future study might usefully examine
detailed PK curves for the same patient on consecutive days under
different conditions of oral intake. A perennial and inherent prob-
lemwith TB drug PK analyses is unpicking whether plasma rifam-
pin levels, defined as the Cmax, or (preferentially) total exposure,
measured as theAUC, is the crucial determinant of drug efficacy at
the cellular level and, if so, what the minimum drug exposure
(measured in plasma) needs to be in order to have a high proba-
bility of efficacy. Evidence for poorer treatment outcomes associ-
ated with impaired pharmacokinetics is, perhaps surprisingly,
somewhat thin and less persuasively demonstrated for rifampin
(38) than for pyrazinamide (6).Moreover, treatment outcomes of
patients in Peru with standardized regimens using these same
drugs and dosages are generally good, implying that efficacy, at
least with the existing four-drug combination therapy, is ade-
quate. We could evaluate treatment outcome and relapse rates
only to 6 months for 60 patients, 5 of whom had an unfavorable
outcome. Given the very low levels of rifampin among patients
cured of disease, further investigation is needed to ascertain
whether a review of the purported normal Cmax level of 8 mg/
liter is warranted. However, some studies have demonstrated that
an increase in the dose of rifampin led to a better treatment out-
come (20). Therefore, if we assume ahighermedian concentration
in those patients who received a higher dose, we could consider
that there is a correlation between the concentration and the treat-
ment outcome.
In addition, we report data only on rifampin here, and patients
might have been cured despite impaired rifampin pharmacoki-
netics because of the effect of the combination therapy (isoniazid,
ethambutol, or pyrazinamide). For this reason, the 8-mg/liter
threshold might be better regarded as desirable rather than neces-
sary.
We have demonstrated markedly deranged rifampin pharma-
cokinetics in a majority of TB patients taking directly observed
therapy in the Peruvian NTP, with delayed absorption and low
drug levels, findings not inconsistent with those of previous work
in other countries. A clarification of the implications of these find-
ings for clinical outcomes is now essential; if outcomes are unaf-
fected, perhaps further thought needs to be given to our existing
paradigm for normal, therapeutically active rifampin pharmaco-
kinetics.
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